Is Ultragenyx Pharmaceutical Inc. (RARE) a Buy, Sell, or Hold?
Ultragenyx Pharmaceutical Inc.
NASDAQ:RARE
$32.03 USD
-$1.19 (-3.58%)
- Volume
- 1.05M
- Average Volume
- 2.2M
- Market Capitalization
- $3.15B
- P/E Ratio
- -5.24
- Dividend Yield
- 0.00%
- Price Target
- $43.00
- Year High
- $39.89
- Year Low
- $18.29
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.02
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Emil D. Kakkis |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | RARE |
| CUSIP | 90400D108 |
| CIK | 0001515673 |
| Web | https://www.ultragenyx.com |
| Phone | 415 483 8800 |
| Currency | USD |
| Employees | 1371 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | -5.08 |
| Payout Ratio | 0.00 |
| Current Ratio | 2.02 |
| Quick Ratio | 1.85 |
| Cash Ratio | 0.54 |
Sales & Book Value
| Annual Sales | $673M |
| Price / Sales | 4.71 |
| Cash Flow | -4.84 |
| Price / Cash Flow | -6.47 |
| Price / Book | -13.65 |
Price Target and Rating
| Average Stock Price Forecast | $43.00 |
| High Stock Price Forecast | $67.00 |
| Low Stock Price Forecast | $30.00 |
| Forecast Upside/Downside | -25.51% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 33 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-5.83 |
| Trailing P/E Ratio | -5.24 |
| PEG Ratio | 1.08 |
| P/E Growth | 1.08 |
| Net Income | $-575M |
| Net Margin | -91.03% |
| Pretax Margin | -90.46% |
| Return on Equity | 1566.94% |
| Return on Assets | -47.02% |
Financials Score
| AltmanZ Score | -4.39 |
| Piotroski Score | 2.00 |
| Working Capital | 332M |
| Total Assets | 1.3B |
| Ebit | -537.36M |
| Market Cap | 3.18B |
| Total Liabilities | 1.52B |
Poll Results
About Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets. The company's portfolio of marketed biologic products addresses several serious diseases. This includes Crysvita (burosumab), an antibody that targets fibroblast growth factor 23, used to treat X-linked hypophosphatemia and tumor-induced osteomalacia. Mepsevii offers enzyme replacement therapy for both pediatric and adult patients suffering from Mucopolysaccharidosis VII. Dojolvi is available for individuals with long-chain fatty acid oxidation disorders, while Evkeeza (evinacumab) provides a treatment option for homozygous familial hy ... percholesterolemia. Ultragenyx also boasts a robust pipeline of investigational therapies. Notable candidates include DTX401, an adeno-associated virus 8 (AAV8) gene therapy for glycogen storage disease type Ia, and DTX301, another AAV8 gene therapy aimed at ornithine transcarbamylase deficiency. Other promising developments feature UX143, a human monoclonal antibody for osteogenesis imperfecta; GTX-102, an antisense oligonucleotide designed for Angelman syndrome; UX701, targeting Wilson disease; and UX053, in development for glycogen storage disease type III. To advance its research and development efforts, Ultragenyx Pharmaceutical Inc. maintains strategic collaboration and licensing agreements with numerous partners, such as Kyowa Kirin Co., Ltd., Saint Louis University, REGENXBIO Inc., Bayer Healthcare LLC, GeneTx, Mereo, University of Pennsylvania, Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc., and Daiichi Sankyo Co., Ltd. The company was founded in 2010 and operates from its headquarters in Novato, California.
2026-07-08 09:08:00
NOVATO, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) released its 2025 Impact Report, detailing the company's work on behalf of patients and families living with rare and ultra-rare diseases. In 2025, Ultragenyx advanced five investigational therapies in pivotal clinical programs with the potential to reach tens of thousands of patients around the world — while continuing to build on years of work to support patients who cannot yet access approved treatments, which have now reached individuals in 50 countries.
Ultragenyx (RARE) Soars 5.2%: Is Further Upside Left in the Stock?
2026-06-29 11:16:09
Ultragenyx (RARE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Ultragenyx: The Setrusumab Reset Creates A Cleaner Rare Disease Opportunity
2026-06-21 11:43:38
Ultragenyx (RARE) is transitioning from a broad pipeline to a focused rare disease platform, entering a high-catalyst period with four approved products and multiple late-stage assets. Despite a recent Phase 3 failure and Q1 2026 net loss, RARE reaffirmed 2026 revenue guidance of $730–$760 million, supported by a scalable commercial base and cost controls. Key near-term catalysts include FDA reviews for DTX401 and UX111 (PDUFA dates in H2 2026) and pivotal Phase 3 Aspire results for GTX-102 in Angelman syndrome.
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-06-19 16:30:00
NOVATO, Calif., June 19, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 44,409 restricted stock units of the company's common stock to 15 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of June 16, 2026, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-06-19 16:30:00
NOVATO, Calif. , June 19, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 44,409 restricted stock units of the company's common stock to 15 newly hired non-executive officers of the company.
2026-06-09 19:32:11
Ultragenyx Pharmaceutical Inc. (RARE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm
2026-06-04 16:36:00
NEW YORK, June 4, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Ultragenyx Pharmaceutical caused the company to misrepresent or fail to disclose the true state of setrusumab's potential and the risk inherent in the study protocols put forth; notably, that, while setrusumab does increase material bone density, this increase does not correlate to a decrease in annualized fracture rates.
Ultragenyx (RARE) Down 13.6% Since Last Earnings Report: Can It Rebound?
2026-06-04 12:35:57
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock?
Frequently Asked Questions
-
What is the current Ultragenyx Pharmaceutical Inc. (RARE) stock price?
-
Ultragenyx Pharmaceutical Inc.(NASDAQ:RARE) stock price is $32.03 in the last trading session. During the trading session, RARE stock reached the peak price of $39.89 while $18.29 was the lowest point it dropped to. The percentage change in RARE stock occurred in the recent session was --3.58% while the dollar amount for the price change in RARE stock was -$-1.19.
-
RARE's industry and sector of operation?
-
The NASDAQ listed RARE is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of RARE?
-
Emil D. Kakkis | Founder, President, Chief Executive Officer & Director
Eric Crombez | Chief Medical Officer & Executive Vice President
Dennis Karl Huang | Chief Technical Operations Officer and Executive Vice President of Gene Therapy Operations
Howard Horn | Executive Vice President of Corporate Strategy & Chief Financial Officer
Karah Herdman Parschauer | Chief Legal Officer & Executive Vice President of Corporate Affairs -
How many employees does RARE have?
-
Number of RARE employees currently stands at 1371. RARE operates from 60 Leveroni Court, Novato, CA 94949, US.
-
Link for RARE official website?
-
Official Website of RARE is: https://www.ultragenyx.com
-
How do I contact RARE?
-
RARE could be contacted at phone #415 483 8800 and can also be accessed through its website. RARE operates from 60 Leveroni Court, Novato, CA 94949, US.
-
How many shares of RARE are traded daily?
-
The average number of RARE shares traded daily for last 3 months was 2.2M.
-
What is the market cap of RARE currently?
-
The market value of RARE currently stands at $3.15B with its latest stock price at $32.03